Enzyme alterable alkylating agents. XI. Clinical trials of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy

Daniel Bakal, Louis E. Goodman, Adolph Ulfohn, Anselmo G. Mamaril, Yale H. Caplan, Simon Calle, Belur S. Bhagavan, Benjamin Witten, Charles E. Williamson, Samuel Sass, Arnold M. Seligman

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical trials of a new water-soluble short half-life alkylating agent (S-73) administered by intra-arterial infusion into 56 patients with a variety of malignant tumors, revealed only limited usefulness. The best responses were seen in a case of Kaposi's sarcoma, a squamous cell carcinoma of the tongue, an epidermoid carcinoma of the cervix, and metastatic carcinoid to liver. In all, there were 5 good responses, 3 fair responses, 36 with no response, and 12 indeterminates. Further modifications in design and structure of S-73 are in progress to probe for greater tumor specificity.

Original languageEnglish (US)
Pages (from-to)217-223
Number of pages7
JournalJournal of Surgical Research
Volume11
Issue number5
DOIs
StatePublished - May 1971

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Enzyme alterable alkylating agents. XI. Clinical trials of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy'. Together they form a unique fingerprint.

Cite this